NASDAQ:TRPX Therapix Biosciences (TRPX) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free TRPX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.09▼$0.1250-Day Range$0.10▼$0.3252-Week Range$0.25▼$4.69Volume95,212 shsAverage Volume1.59 million shsMarket Capitalization$351,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Therapix Biosciences alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Therapix BiosciencesRead More Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. TRPX Stock News HeadlinesDecember 12, 2023 | benzinga.comAnixa Biosciences Stock (NASDAQ:ANIX), Analyst Ratings, Price Targets, PredictionsAugust 23, 2023 | investing.comSagimet Biosciences Inc (SGMT)May 5, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. August 1, 2023 | seekingalpha.comPBIO Pressure BioSciences, Inc.January 19, 2022 | thestreet.comCannabis, Coats, and Social Media: The Good, Bad, and Ugly of 2017's IPOsSee More Headlines Receive TRPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Therapix Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/20/2018Today5/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:TRPX CUSIPN/A CIK1611746 Webtherapixbio.com Phone972-3616-7055FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares3,510,000Free FloatN/AMarket Cap$351,000.00 OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Ascher Shmulewitz (Age 63)Chairman & Interim CEO Dr. Adi Zuloff-Shani (Age 51)Chief Technology Officer Mr. Oz Adler CPA (Age 32)Chief Financial Officer Key CompetitorsAthersysNASDAQ:ATHXAptevo TherapeuticsNASDAQ:APVOAmpio PharmaceuticalsNYSE:AMPEChina SXT PharmaceuticalsNASDAQ:SXTCAditxtNASDAQ:ADTXView All Competitors TRPX Stock Analysis - Frequently Asked Questions How were Therapix Biosciences' earnings last quarter? Therapix Biosciences Ltd. (NASDAQ:TRPX) announced its earnings results on Monday, August, 20th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.24. What other stocks do shareholders of Therapix Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Therapix Biosciences investors own include Zynerba Pharmaceuticals (ZYNE), Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), SCYNEXIS (SCYX), Sangamo Therapeutics (SGMO), Tilray (TLRY), Corbus Pharmaceuticals (CRBP) and VBI Vaccines (VBIV). This page (NASDAQ:TRPX) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe only AI company you should be looking atBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Therapix Biosciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
